These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33252556)

  • 41. Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases.
    Grasmeier MK; Langmann AF; Langmann P; Treiber M; Thaler MA; Luppa PB
    Therap Adv Gastroenterol; 2021; 14():17562848211037849. PubMed ID: 34434255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P
    Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
    Buhl S; Dorn-Rasmussen M; Brynskov J; Ainsworth MA; Bendtzen K; Klausen PH; Bolstad N; Warren DJ; Steenholdt C
    Scand J Gastroenterol; 2020 Aug; 55(8):884-890. PubMed ID: 32631131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.
    Barberio B; D'Incà R; Facchin S; Dalla Gasperina M; Fohom Tagne CA; Cardin R; Ghisa M; Lorenzon G; Marinelli C; Savarino EV; Zingone F
    Inflamm Bowel Dis; 2020 Apr; 26(5):756-763. PubMed ID: 31504536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
    Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
    Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
    Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
    Imaeda H; Andoh A; Fujiyama Y
    J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease.
    Yoshimura N; Yokoyama Y; Sako M; Aoyama N; Hirai F; Sawada K; Kashiwagi N; Suzuki Y
    Cytokine; 2019 Aug; 120():54-61. PubMed ID: 31003189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases.
    Jung ES; Choi KW; Kim SW; Hübenthal M; Mucha S; Park J; Park Z; Ellinghaus D; Schreiber S; Franke A; Oh WY; Cheon JH
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1727-1735. PubMed ID: 30851117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
    Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A
    PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
    Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
    BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
    Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.